T2 Biosystems

T2 Biosystems is a developer of a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single instrument. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Its initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need.

The Company is utilizing its proprietary T2 Magnetic Resonance platform to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.

Company Growth (employees)
Lexington, US
Size (employees)
178 (est)+6%
T2 Biosystems was founded in 2006 and is headquartered in Lexington, US

Key People/Management at T2 Biosystems

Tom Lowery

Tom Lowery

Vice President of Diagnostics Research & Development
Rahul Dhanda

Rahul Dhanda

Vice President of Global Support Services Marketing

T2 Biosystems Office Locations

T2 Biosystems has offices in Lexington and Wilmington
Lexington, US (HQ)
101 Hartwell Ave
Wilmington, US
231 Andover St
Show all (2)

T2 Biosystems Financials and Metrics

T2 Biosystems Financials

T2 Biosystems's revenue was reported to be $4.1 m in FY, 2016

Revenue (Q2, 2017)

956 k

EBIT (Q2, 2017)

(13.9 m)

Market capitalization (22-Dec-2017)

133.2 m

Cash (30-Jun-2017)

46.1 m
T2 Biosystems's current market capitalization is $133.2 m.
USDFY, 2014FY, 2015FY, 2016


119 k2.8 m4.1 m

Revenue growth, %


R&D expense

19.8 m25.4 m24 m

General and administrative expense

11 m19.1 m24.1 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


188 k564 k1 m1.1 m990 k1.1 m941 k956 k

R&D expense

5.9 m6.7 m6.2 m6.6 m6.4 m5.2 m6.6 m7.1 m

General and administrative expense

4.5 m4.4 m5.2 m6.2 m6.1 m5.9 m5.9 m5.8 m

Operating expense total

10.3 m11.1 m12.2 m13.8 m14.3 m13 m14.1 m14.9 m
USDFY, 2014FY, 2015FY, 2016


73.8 m73.7 m73.5 m

Accounts Receivable

201 k369 k327 k


115 k683 k820 k

Current Assets

75.3 m75.6 m75.4 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


65.3 m53.3 m40.1 m59.5 m50.2 m75.1 m58.8 m46.1 m

Accounts Receivable

88 k389 k378 k360 k288 k379 k409 k981 k


252 k569 k1.1 m1.3 m1.4 m1.3 m489 k1 m

Current Assets

66.4 m54.9 m42.7 m62 m52.5 m77.8 m60.7 m48.8 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(31.4 m)(45.3 m)(54.8 m)

Depreciation and Amortization

691 k1.5 m2.3 m

Accounts Receivable

(201 k)(168 k)42 k


(1.2 m)(568 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.6 m)(21.6 m)(11.6 m)

Depreciation and Amortization

600 k

Accounts Receivable

88 k(188 k)378 k360 k288 k379 k409 k


252 k(453 k)1.1 m1.3 m1.4 m
Y, 2017

Financial Leverage

5.2 x
Show all financial metrics

T2 Biosystems Operating Metrics

T2 Biosystems's Patent Applications was reported to be 50 in FY, 2016
FY, 2016



Patents Issued


Patent Applications

Show all operating metrics

T2 Biosystems Market Value History

T2 Biosystems's Web-traffic and Trends

T2 Biosystems Online and Social Media Presence

T2 Biosystems Company Life and Culture

You may also be interested in